" OTC " StockShark is Honored to welcome - TechniScan ,Inc. (OTCBB : TSNI )
" OTC " StockShark is incredibly head over heals for TSNI ..It is truly awesome when We come across a companies technology We strongly
Believe in. You get the very best of both worlds with TSNI . We love TSNI as a stock play and believe we have a huge power play on our hand
Hands but We also strongly believe in the TechniScan's Breast Imaging technology ( Product ) .The stock has just recently started trading in
October of this year. Fresh out of the gate TSNI has done everything right on . Instead of opening at some crazy price only to have it fall right away
( We have seen this time after time ) TSNI shot out of a cannon from the stock's opening price of $.10 cents to a high of $ 2.00 . TSNI has now
leveled off and closed Friday 12/5/09 at $ 1.10 I our opinions We mentioned TSNI is about to make a very big move upwards at the same
time issuing some huge Press Releases . Do not miss out on TSNI this is the savvy investor's dream play because this is the ground floor
bottom for TSNI . Do not miss out on TechniScan , Inc. ( OTCBB ; TSNI ) Monday is only going to be the beginning of what We believe to be
a " Monster " run for TSNI. Below is an introduction to TSNI explaining the company's amazing Breast Imaging Technology along with "Big "
strategic partnerships with Nvidia and many others . This being a great starting point for your own Due Diligence gearing up for " The TSNI
coming out party slated to start this Monday 12/7/09.. Get in the game !!!
About TechniScan, Inc.
Based in Salt Lake City, Utah, TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. The system, known as Svara™, uses a process called Warm Bath Ultrasound (WBU™) to provide physicians with automated, 3D, ultrasound images of the physical structures within the breast. TechniScan’s Warm Bath Ultrasound (WBU™) imaging device (Svara™) is limited by US law to investigational use unless and until cleared by the FDA
Company Overview
About TechniScan, Inc.
TechniScan, Inc. is a medical device company engaged in the development and commercialization of an automated,
repeatable ultrasound breast imaging and diagnostic system.
SVARATM, TechniScan's automated 3D whole breast ultrasound imaging system, is designed to provide physicians with
a repeatable, non-invasive imaging tool of unrivaled sensitivity and specificity for the early and accurate detection of
cancers and abnormalities. This operator-independent, automated breast imaging system is a software-controlled, fixed
room, ultrasound system designed to maximize patient comfort during the scanning process. It enables the operator to
perform an automated whole breast examination while the patient lies prone on the system’s examination table with the
breast comfortably suspended in a warm water bath maintained near skin temperature. The ultrasound array is moved
in a continuous scan that collects a complete series of successive 3-D images of the breast. The resulting images can
then be viewed on a DICOM review station. The quality of the images generated by the system is relatively independent
of operator skill and experience (unlike conventional breast ultrasound). TechniScan does not use ionizing radiation and
this technology does not require breast compression. The TechniScan system additionally records, stores and catalogs
data from each scan of each patient to a centralized database.
The system includes unique subscription software that supports the business model by providing support for many top
level functions and also support system financing – i.e., through subscriptions fees. The software allows TechniScan to
provide radiologists with a portal through which it can deliver a wide variety of valuable services that will allow them to
archive and retrieve, compare images to other similar data sets, store their own images and diagnostic notes, collaborate
with others, and correlate information with diagnostic results and outcomes.
Strategic Partnerships : NVIDIA , ESAOTE , and LCN Technology .
Financial Highlights
* Became a public company through reverse merger on
Oct. 9, 2009.
* Has generated $24 million in equity financing to date,
plus $5 million as a result of NIH grants.
* Huge market opportunity:
Approximately 9,000 FDA certified facilities in the
* U.S. are projected to have spent over $2.5 billion in
2008 for breast cancer detection and diagnostic
imaging equipment;
* US market expected to grow at a CAGR of 16.7%
per year.
* Strategic partnership with Italy-based, Esaote, the
fastest-growing ultrasound company in the world with
more than 60,000 imaging systems deployed globally.
* Esaote owns 12% of the Company’s outstanding
shares and has submitted the Company’s 510k submission
to the Food and Drug Administration/
* National Institute of Health in June 2009.
Esaote has place orders and prepaid for three systems,
pending approval.
* Fast Track Award of $3.2 million: Year 3 clinical deployments
began in July 2009.
* Have been awarded two other SBIR grants totaling
$275,000.
* Six subscription-based systems to be deployed within
eight months of receiving financing.
Competitive Advantages
* Automated
3D whole breast ultrasound
* Comfortable, no breast compression
Scan time 8 min/breast – less than current ultrasound or MRI
Repeatable
* * Storage, archiving, comparison analysis, correlative analysis
and other functions delivered to the desktop
* Unique, quantitative high resolution images
Operator independent
Intellectual Property
TechniScan currently has six patents awarded, eight patents pending, two allowed, two provisional patents and two
pending foreign applications. All listed inventors have assigned their rights in the patents to TSNI except for the
University of Utah, which has granted an exclusive, irrevocable and permanent world-wide license to the intellectual
property, pursuant to an Amended and Restated License Agreement, dated January 10, 2002. TSNI patent rights,
proprietary know-how, and similar intellectual property are material to its competitive position. In addition to its
patents, TSNI has a registered trademark in the United States for "TechniScan Medical Systems."
Svara™ Warm Bath Ultrasound (WBU™)
TechniScan Medical Systems (TMS) is dedicated to improving the diagnosis of breast cancer. To accomplish this mission, TMS is developing an operator-independent, automated breast imaging system that uses ultrasound.
TechniScan Medical Systems is in the process of applying for 510(k) clearance of the WBU System. The system is not cleared for sale at this time.
The TechniScan WBU System is a software-controlled, fixed room, ultrasound system. The system is designed to maximize patient comfort during the scanning process by enabling the operator to perform an automated whole breast examination while the patient lies prone on the system’s examination table with the breast comfortably suspended in a warm water bath maintained near skin temperature. The ultrasound array is moved in a continuous scan so that a complete series of 2-D image slices of the breast are collected. The resulting images can then be viewed on a DICOM review station.
The quality of the images generated by the system is relatively independent of operator skill and experience (unlike conventional breast ultrasound). Of note, ultrasound breast imaging uses no ionizing radiation and does not require breast compression.
Warm Bath Ultrasound (WBUTM) System Image Review
A complete description of image review and analysis will be released after 510(k) clearance by the FDA of the WBU Imaging System.
The WBU Imaging System produces a series of coronal slices of the breast from the nipple to near the chest wall in millimeter-scale increments that are exported in DICOM format from the system to the customer’s PACS system or CD-ROM. The breast is scanned without compression so the location of any lesion or abnormality on the images can be directly correlated to its location in the physical breast.
The clinician will be able to view the images on an image review station. Because the sets of images are exported in a standard DICOM format, they are viewable with DICOM image review software. A case study example is described below.
Case Study
A 70-year old woman who presented with palpable breast masses and the diagnostic mammography views show circumscribed, partially obscured masses in dense breast parenchyma. Figure 1 shows the mammography images and the TechniScan WBU images are shown in Figure 2.
1086-Mammo-5_for TMS-106
Figure 1. Mammography views showing circumscribed, partially obscured masses in dense breast parenchyma.
TMS-106 Refletion images for website.tif
Figure 2. WBU images taken at the 9 o’clock position based on findings with mammography. Images are of the coronal (left), cranial/caudal (middle), and sagittal views (right).
Clinical Utility
TechniScan Medical Systems (TMS) has filed an application with the FDA for 510(k) marketing clearance of the WBU™ Imaging System. A comprehensive clinical utility statement will be released after 510(k) clearance by the FDA.
Remember we suggest you always do your own due diligence and seek the advice of your broker.
We here at "OTC" StockShark do our very best to bring you companies that have the potential to turn our members
a profit...Speaking of profits it is always important to take them when you can , even a small profit is better than a kick in the teeth...
Do not forget to add us to your contacts so we do not end up in your spam box , Thank you......
STOCKSHARK , LLC is OTC STOCKSHARK.COM Disclosure: StockShark , LLC has been compensated $3,000 from a non-controlling 3rd party.This is for a 1 week of Market Awareness program. StockShark , LLC is not a registered investment adviser or a broker/dealer. StockShark , LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Click here to Unsubscribe from our alert list
